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trol in patients with mild asthma.5 A goal of clini-
cal investigation should be to provide new infor-
mation and a firm scientific rationale from which 
to devise the next set of guidelines.
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Beclomethasone and Albuterol in Mild Asthma
To the Editor: In the study of rescue use of bec-
lomethasone and albuterol in a single inhaler for 
mild asthma reported by Papi et al. (May 17 issue),1 
the morning peak expiratory flow rate (based on 
peak-flow diaries) was the primary end point, al-
though there is enough reason to doubt its clini-
cal relevance, its validity, and its physiological 
meaning in a disease that predominantly affects 
smaller airways. The peak expiratory flow rate re-
flects mainly central-airway mechanics2 and is in-
sensitive for the monitoring of peripheral-airway 
patency. Only because no Bonferroni correction 
was used, the morning peak expiratory flow rate 
— but not the evening peak expiratory flow rate 
or variability in peak expiratory flow rate — was 
marginally significantly different (P = 0.04) between 
the as-needed combination group and the as-need-
ed albuterol group, whereas the secondary end 
points of forced expiratory volume in 1 second and 
forced vital capacity (percent of the predicted val-
ue) proved to be much more sensitive in detecting 
a treatment effect. A similar situation was report-
ed previously,3 and the study by Papi et al. once 
again illustrates that measures of peak expiratory 
flow rate are insensitive and therefore, in my opin-
ion, do not reflect the disease adequately.
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To the Editor: The conclusions by Papi and col-
leagues with respect to the effectiveness and med-
ication-sparing capacity of inhaled beclometha-
sone–albuterol as intermittent therapy for mild 
persistent asthma are based on their study of 
adults. The application of this method to children 
requires proof of principle. Lung growth, which 
affects treatment outcomes over time in children, 
could obviously not be accounted for in their study.
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The Authors Reply: Merkus is concerned that the 
use of the morning peak expiratory flow rate, based 
on peak-flow diaries, may be misleading because 
it is insensitive and may not reflect small-airway 
abnormalities. Measurement of the peak expiratory 
f low rate is still recommended in international 
guidelines1 for monitoring asthma. It is incorrect 
to state that the peak expiratory flow rate did not 
differ significantly between the groups in our 
study, since the morning peak expiratory flow rate 
was indeed sensitive enough to detect significant 
differences, in direct comparisons of the experi-
mental treatment (as-needed use of combination 
albuterol–beclomethasone and regular use of bec-
lomethasone) and the control treatment (as-needed 
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use of albuterol). To the best of our knowledge, 
there is no single test of airway function that re-
flects the prevalent site of airflow obstruction in 
asthma, and there is no evidence from clinical tri-
als that physiological measures that are thought 
to reflect peripheral airways correlate better with 
respiratory symptoms than other tests of airway 
function.2 We agree that since the objective of asth-
ma treatment is to ensure clinical control, it would 
be of value to design trials that involve patient-
centered outcomes.3
We also agree with Terracciano and colleagues 
that treatments for asthma should be tested in 
children with mild asthma. A randomized clinical 
trial sponsored by the National Heart, Lung, and 
Blood Institute is currently under way to address 
this important issue (the Childhood Asthma 
Research and Education [CARE] Network Trial 
— Treating Children to Prevent Exacerbations 
of Asthma [TREXA]; ClinicalTrials.gov number, 
NCT00394329).
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A National Survey of Physician–Industry Relationships
To the Editor: Campbell et al. (April 26 issue)1 
present disturbing evidence that many physicians 
accept inappropriate gifts from industry. Physicians 
should not accept such gifts, because the reciproc-
ity they engender is known to affect prescribing 
decisions, which may harm patients and increase 
the cost of care.
The authors should have known, however, that 
an American Medical Association (AMA) policy 
has addressed the ethics regarding industry gifts 
to physicians since 1990,2 more than a decade be-
fore the Pharmaceutical Research and Manufactur-
ers of America (PhRMA) code was implemented in 
2002. In fact, the PhRMA code was based largely 
on the AMA’s opinion E-8.061, as even a cursory 
glance will show.
Many gifts cited by Campbell et al., such as re-
imbursement for admission and travel to continu-
ing medical education (CME) meetings and tick-
ets to cultural and sporting events, are clearly 
prohibited under the AMA code. The AMA calls 
on pharmaceutical companies and physicians to 
abide by their respective codes of conduct and to 
neither offer nor accept inappropriate gifts, for 
the benefit of patients and the public.
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To the Editor: Voluntary guidelines issued by 
the pharmaceutical industry in 2002 addressing 
interactions with health professionals include a ban 
on direct payments to physicians for attendance 
at CME or other conference events. According to 
the guidelines, any industry support for confer-
ences or courses should be provided indirectly 
through event organizers.1 Despite this guideline, 
Campbell et al. state that 35% of the physicians 
in their survey reported receiving reimbursement 
for “costs of travel, time, meals, lodging, or other 
personal expenses for attending meetings,” “free 
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